Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

ObsEva

Thumbnail
July 06, 2020

Obseva shows why red flags are worth heeding

A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.

Thumbnail
June 24, 2020

Myovant socks it to Orilissa

Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.

Article image
Vantage logo
March 06, 2020

Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash

Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.

Article image
Vantage logo
December 09, 2019

Obseva’s linzagolix blooms but safety questions remain

Article image
Vantage logo
November 07, 2019

No baby joy for Obseva’s expectant investors

Article image
Vantage logo
September 06, 2019

Upcoming events – Obseva's first fibroid foray and Newron's test in Retts

Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.

Article image
Vantage logo
April 18, 2019

Upcoming events – pivotal readouts for Intra-Cellular and Myovant

Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.

Article image
Vantage logo
December 06, 2018

Bayer puts the brakes on vilaprisan trials following safety concerns

The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.

Article image
Vantage logo
August 22, 2018

Esmya rejection hits Allergan's streamlining

A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.

Article image
Vantage logo
July 24, 2018

Red flags for Abbvie’s elagolix green light

Vantage logo
June 19, 2018

Obseva needs more to beat Abbvie in endometriosis

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.